Novartis buys HySolv technology from BTG

- Last updated on GMT

Related tags: Drug, Drugs, Pharmacology

Swiss drug major Novartis will UK specialty pharma firm BTG up to $10m (€7m) for its HySolv drug delivery technology.

As the name suggests HySolv uses a patent solvent system to improve the solubility of hydrophobic drugs. The technology was developed by recent BTG acquisition US group Protherics.

BTG CEO Louise Makin said that the deal is in line with the firm’s plan to realise value from its assets “while continuing to build value in our development pipeline and establishing our US sales and marketing operations​.”

Although Novartis has not yet commented on its latest acquisition the nature of the HySolv technology suggests it will be applied to both traditional small molecule drug candidates as well as biologics, for which solubility is often an issue.

Related news

Show more

Related products

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers